Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Ahmet Sevindik

Advertisement
Set Alert for Articles By Ahmet Sevindik

Latest From Ahmet Sevindik

Could The City Hospitals Project Be A Bit Of A Turkey?

As Turkey’s City Hospitals project goes underway, with the first few hospitals already up and running, big medtech players are swooping down to capitalize on this opportunity which promise to boost the Turkish market by up to TRY2bn. However, intense competition, as well as basic problems that had been plaguing companies operating in that country, persists and still needs to be resolved.

Turkey Commercial

Siemens Healthineers' Sevket On: Growing Beyond Imaging And IVDs In Turkey

Siemens Healthineers last month won a five-year contract to oversee the clinical lab service operations for two new hospitals in Turkey. The deal, expected to bring in at least €30m in revenue for Siemens, is part of Turkey's initiative to boost its health care system by modernizing existing, as well as building brand new facilities. Sevket On, General Manager of Siemens Healthineers Turkey, provides more insight into this deal as well as the group's broader strategies to capitalize on the growth opportunities presented by Turkey's health care expansion plans.

Turkey In Vitro Diagnostics

Turkey Plans To Facilitate Orphan Drug Licensing

Turkey has been working on a new draft guide to increase access to orphan drugs, focusing on accelerating licensing procedures, and other incentives.

Policy Turkey

Turkey: Produce Selected Drugs Locally Or Lose Reimbursement

Turkey’s public payer body has said it will halt reimbursement of 54 products from 2018 unless manufacturers, including several multinationals, agree to start local production within a year.

Turkey Policy

Turkey Grapples With Spinraza Cost As Patients Seek Access

Families of spinal muscular atrophy patients in Turkey are demanding immediate access to Biogen’s Spinraza following its US approval in December. Its public payer is in discussions over possible reimbursement of the high-priced imported drug but the company is said to have shown no pricing flexibility so far.

Turkey Pricing Debate

Turkish Govt Using Purchasing To Foster Local Generic Production

Facing difficulties in attracting greenfield pharma investments in the production of original and high-tech drugs, the Turkish Government is leveraging its purchasing power for generics to encourage local manufacture in this sector. Faced with the threat of exclusion from reimbursement, some multinationals are now building up their capacity in the country.

Turkey Manufacturing
See All
Advertisement
UsernamePublicRestriction

Register